Maxime Parisotto

Dr. Maxime Parisotto

Montreal Clinical Research Institute, Montréal, Quebec, Canada
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Science Advances
Verified
Journal Article
Open access
MMMohamed Abu el Maaty
Mohamed Abu el Maaty
JTJulie Terzic
Julie Terzic
CKCéline Keime
Céline Keime
DRDaniela Rovito
Daniela Rovito
RLRégis Lutzing
Régis Lutzing
DMDaniel Metzger
Daniel Metzger
Prostate cancer (PCa) is a leading cause of cancer-related deaths. The slow evolution of precancerous lesions to malignant tumors provides a broad time frame for preventing PCa. To characterize prostatic intraepithelial neoplasia (PIN) progression, we conducted longitudinal studies on Pten (i)pe−/− mice that recapitulate prostate carcinogenesis in humans. We found that early PINs are hypoxic and that hypoxia-inducible factor 1 alpha (HIF1A) signaling is activated in luminal cells, thus enhancing malignant progression. Luminal HIF1A dampens immune surveillance and drives luminal plasticity, leading to the emergence of cells that overexpress Transglutaminase 2 (TGM2) and have impaired androgen signaling. Elevated TGM2 levels in patients with PCa are associated with shortened progression-free survival after prostatectomy. Last, we show that pharmacologically inhibiting HIF1A impairs cell proliferation and induces apoptosis in PINs. Therefore, our study demonstrates that HIF1A is a target for PCa prevention and that TGM2 is a promising prognostic biomarker of early relapse after prostatectomy.

14 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MPMaxime Parisotto
Maxime Parisotto
NVNhung Vuong-Robillard
Nhung Vuong-Robillard
PKPaloma Kalegari
Paloma Kalegari
TMThulaj Dattatraya Meharwade
Thulaj Dattatraya Meharwade
LJLoick Joumier
Loick Joumier
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
Pancreatic cancer (pancreatic ductal adenocarcinoma: PDAC) is one of the most aggressive neoplastic diseases. Metformin use has been associated with reduced pancreatic cancer incidence and better survival in diabetics. Metformin has been shown to inhibit PDAC cells growth and survival, both in vitro and in vivo. However, clinical trials using metformin have failed to reduce pancreatic cancer progression in patients, raising important questions about molecular mechanisms that protect tumor cells from the antineoplastic activities of metformin. We confirmed that metformin acts through inhibition of mitochondrial complex I, decreasing the NAD+/NADH ratio, and that NAD+/NADH homeostasis determines metformin sensitivity in several cancer cell lines. Metabolites that can restore the NAD+/NADH ratio caused PDAC cells to be resistant to metformin. In addition, metformin treatment of PDAC cell lines induced a compensatory NAMPT expression, increasing the pool of cellular NAD+. The NAMPT inhibitor FK866 sensitized PDAC cells to the antiproliferative effects of metformin in vitro and decreased the cellular NAD+ pool. Intriguingly, FK866 combined with metformin increased survival in mice bearing KP4 cell line xenografts, but not in mice with PANC-1 cell line xenografts. Transcriptome analysis revealed that the drug combination reactivated genes in the p53 pathway and oxidative stress, providing new insights about the mechanisms leading to cancer cell death.

23 November 2018 in Molecular & Cellular Oncology
Verified
Journal Article
Closed access
MPMaxime Parisotto
Maxime Parisotto
EGElise Grelet
Elise Grelet
RBRana El Bizri
Rana El Bizri
DMDaniel Metzger
Daniel Metzger
We report that Pten (phosphatase and tensin homologue) ablation in prostatic epithelial cells of adult mice promotes cell proliferation to generate prostatic intraepithelial neoplasia. Moreover, our results demonstrate that proliferating Pten-deficient cells undergo replication stress and exhibit a DNA damage response, leading to cell senescence, as seen in oncogene-induced senescence.

10 May 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AHAudrey Hébert
Audrey Hébert
MPMaxime Parisotto
Maxime Parisotto
MRMarie-Camille Rowell
Marie-Camille Rowell
ADAlexandra Doré
Alexandra Doré
ARAna Fernandez Ruiz
Ana Fernandez Ruiz
ASAndreea Ruxandra Schmitzer
Andreea Ruxandra Schmitzer
We present the design and synthesis of a small library of substituted biguanidium salts and their capacity to inhibit the growth of pancreatic cancer cells. We first present their in vitro and membrane activity, before we address their mechanism of action in living cells and in vivo activity. We show that phenylethynyl biguanidium salts possess higher ability to cross hydrophobic barriers, improve mitochondrial accumulation and anticancer activity. Mechanistically, the most active compound, 1b, like metformin, activated AMPK, decreased the NAD+/NADH ratio and mitochondrial respiration, but at 800-fold lower concentration. In vivo studies show that compound 1b significantly inhibits the growth of pancreatic cancer xenografts in mice, while biguanides currently in clinical trials had little activity.

3 November 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
MPMaxime Parisotto
Maxime Parisotto
NVNhung H. Vuong
Nhung H. Vuong
PKPaloma Kalegari
Paloma Kalegari
TMThulaj Dattatraya Meharwade
Thulaj Dattatraya Meharwade
LJLoick Joumier
Loick Joumier
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
Pancreatic cancer (pancreatic ductal adenocarcinoma: PDAC) is one of the most aggressive neoplastic diseases. Metformin use was associated with reduced pancreatic cancer incidence or better survival in diabetics. Metformin has been shown to inhibit PDAC cells survival and growth in vitro and in vivo. However, clinical trials using metformin failed to decrease pancreatic cancer progression in patients, raising important questions about molecular mechanisms that protect tumor cells from the antineoplastic activities of metformin. We confirm that metformin acts through inhibition of mitochondrial complex I, decreasing the NAD+/NADH ratio and that NAD+/NADH homeostasis determines metformin sensitivity in several cancer cell lines. Metabolites that can restore the NAD+/NADH ratio turned PDAC cells resistant to metformin. In addition, metformin treatment of PDAC cell lines induced a compensatory NAMPT expression increasing the pool of cellular NAD+. The NAMPT inhibitor FK866 sensitized PDAC cells to the antiproliferative effects of metformin in vitro and decreased cellular NAD+ pool. Intriguingly, FK866 combined with metformin increased survival in mice bearing KP4 cells xenografts but not in mice with PANC1 xenografts. Transcriptome analysis revealed that the drug combination reactivated genes in the p53 pathway and oxidative stress providing new insights about the mechanisms leading to cancer cell death.

16 October 2018 in Supramolecular Chemistry
Verified
Journal Article
Closed access
AHAudrey Hebert
Audrey Hebert
MPMaxime Parisotto
Maxime Parisotto
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
ASAndreea Ruxandra Schmitzer
Andreea Ruxandra Schmitzer
Alkylbiguanidium salts show membrane perturbing properties toward simple phospholipid bilayer (liposomes) and complex phospholipid membranes (bacterial membranes). Compared to metformin and phenformin, alkylbiguanidium salts induce a more significant permeabilization of the phospholipid membranes, leading to highly selective H+/OH− ion transport and subsequent depolarization of the membrane. Although alkylbiguanidium salts with shorter C6 and C8 chains are too hydrophilic to be inserted into the membrane and perturb it, those with C10, C12, C14, and C16 alkyl chains show high membrane permeabilization and depolarization activity. In addition, the C10, C12, and C14 compounds possess interesting antimicrobial activity, and, at concentrations close to their minimal inhibitory concentrations, they show low hemolytic activity and toxicity. Graphical Abstract